A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

663

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Neoplasms

Interventions

BIOLOGICAL: Pasritamig
OTHER: Placebo
DRUG: Best Supportive Care (BSC)

Sponsor

Janssen Research & Development, LLC